Wall Street Zen Upgrades Bruker (NASDAQ:BRKR) to Buy

Key Points

• Wall Street Zen upgraded Bruker from hold to buy, adding to a mixed analyst picture that still leaves the stock with a consensus hold rating and an average price target of $50.54.
• Bruker reported better-than-expected Q1 results, posting $0.31 EPS versus the $0.23 estimate and revenue of $823.4 million versus $795.6 million expected, while also issuing FY 2026 EPS guidance of 2.10 to 2.15.
• The stock traded up 1.0% to $44.16, and institutional ownership remains high at 79.52%, with several hedge funds significantly increasing their stakes in recent quarters.

Bruker (NASDAQ:BRKR - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

Several other research analysts also recently commented on the stock. TD Cowen raised their price target on shares of Bruker from $43.00 to $45.00 and gave the stock a "hold" rating in a research note on Thursday. Barclays raised their price target on shares of Bruker from $45.00 to $53.00 and gave the stock an "overweight" rating in a research note on Thursday. The Goldman Sachs Group reduced their price target on shares of Bruker from $40.00 to $35.00 and set a "sell" rating on the stock in a research note on Friday, February 13th. Weiss Ratings raised shares of Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, April 24th. Finally, UBS Group raised their price target on shares of Bruker from $40.00 to $45.00 and gave the stock a "neutral" rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $50.54.

Bruker Trading Up 1.0%

BRKR stock opened at $44.16 on Friday. The company has a market capitalization of $6.72 billion, a PE ratio of -184.00, a P/E/G ratio of 2.62 and a beta of 1.12. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22. The firm's 50-day moving average is $37.26 and its 200 day moving average is $42.06. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm's revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts anticipate that Bruker will post 2.12 EPS for the current year.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares of the company's stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.20% of the company's stock.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently modified their holdings of BRKR. Orbis Allan Gray Ltd purchased a new stake in shares of Bruker in the 2nd quarter worth approximately $192,735,000. Price T Rowe Associates Inc. MD lifted its position in shares of Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock worth $111,488,000 after purchasing an additional 2,289,269 shares during the period. AQR Capital Management LLC lifted its position in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the period. Franklin Resources Inc. lifted its position in shares of Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock valued at $108,796,000 after buying an additional 1,756,460 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Bruker by 222.6% during the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company's stock valued at $86,663,000 after buying an additional 1,269,316 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.